Associate Professor Sasha Senthi is an internationally recognised Radiation Oncologist and supports patients with the latest radiation therapy techniques, including stereotactic radiation using CyberKnife. 

He is recognised for personalised care that achieves the best possible individual outcomes, prioritising quality of life and patient wellness throughout each person's cancer journey. A/Prof Senthi welcomes direct contact email sasha.senthi@aro.co.nz

Biography

A/Prof Senthi attained his Bachelor of Human Biology (BHB) and Bachelor of Medicine, Bachelor of Surgery (MBChB) at the University of Auckland and completed Radiation Oncology training at leading centres across the world. He completed initial training at the Sir Peter MacCallum Cancer Centre in Melbourne, Australasia's largest dedicated cancer centre. 

He then became the first New Zealander to undertake a fully funded clinical research fellowship in Stereotactic Radiation (SABR or SBRT) at VU Medical Centre (VUMC) in Amsterdam, The Netherlands, completing his PhD.A/ Prof Senthi also holds a Master of Public Health from Harvard University which he completed on scholarship.

A/Prof Senthi has over 15 years of specialised clinical experience, focusing best practice care via cutting edge technologies. He is significantly involved in clinical research, quality assurance and medical education. 

In 2016 he was awarded the Victorian Cancer Agency’s clinical research fellowship and established a laboratory to optimise the combination of immunotherapy and stereotactic radiation. He has been both a board member and the Chair of the Scientific Committee of the Trans Tasman Radiation Oncology Group (TROG), which oversees and prioritises radiation therapy research in Australia and New Zealand. 

As an Associate Professor at Monash University, Melbourne, he actively supervises and mentors emerging medical professionals and PhD students in both clinical and laboratory settings. He is widely published in leading peer-reviewed journals that define the field of radiation oncology, in particular the use of stereotactic radiotherapy.

A/Prof Senthi treats a broad range of malignancies with a special interest in those needing stereotactic radiotherapy and oligometastatic (stage IV) cancers. He is a recognised expert in the most advanced techniques including optimizing the use of the CyberKnife.

Publications

• Palma, D., Senthi, S. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. The Lancet 393.10185 (2019): 20251-2058.
• Senthi, S. et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. The Lancet Oncology 13.8 (2012): 802-809.
• Senthi, S. et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiotherapy and Oncology 106.3 (2013): 276-282.
• Senthi, S. et al. Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes. Journal of thoracic disease 5.2 (2013): 116.
• Huang, K. Senthi S. et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiotherapy and Oncology 109.1 (2013): 51-57.

Auckland